Floatz logo

GEMOGENOVATUCEL-T

Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

Gradalis, Inc.Cell therapyPhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor cohort.

Asset / SponsorPhaseRating
Cixutumumab
National Cancer Institute (NCI)
Phase 2BB
Irinotecan
Gradalis, Inc.
Phase 3BB
Xaliplatin
National Cancer Institute (NCI)
Phase 2BB
MELPHALAN
M.D. Anderson Cancer Center
Phase 2B
Nivestim
M.D. Anderson Cancer Center
Phase 2B

View all 35 →

Same molecule, other indications

GEMOGENOVATUCEL-T is also rated in:

uterine cancerDormant
B
Indicative · Phase 2
57 / 100
View asset →
Ewing sarcomaDormant
B
Indicative · Phase 3
57 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative · Phase 2
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →